Business
Immune Therapeutics, Inc., Appoints Two New Board Members
Immune Therapeutics, Inc., Appoints Two New Board Members.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nImmune Therapeutics, Inc., Appoints Two New Board Members\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nImmune Therapeutics, Inc., Appoints Two New Board Members\nPR Newswire\nORLANDO, Fla., March 3, 2016\n\n\n\nORLANDO, Fla., March 3, 2016 /PRNewswire/ -- Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system, today announced the appointment of two new members to its Board of Directors: Clifford A. Selsky, Ph.D., MD, and Paul Akin.\n\n\"Paul Akin and Dr. Selsky 's breadth of knowledge and experience will provide invaluable insight to Immune as we continue to grow the business and strive to deliver innovative therapies in emerging nations,\" said Noreen Griffin, CEO.\n\n\"I'm pleased to welcome both Paul Akin and Dr. Clifford Selsky to the board. Paul brings an extraordinary depth of financial experience developed across his operating and board roles, while Dr. Selsky brings critical perspective as a scientist, physician and patient advocate,\" said Chris Pearce COO.\n\nPaul Akin brings to Immune more than 25 years of leadership experience; he is currently the CEO/Executive Chairman of Collier Warehouse Group (San Francisco). During his tenure as CEO and Executive Chairman of Collier, the company has seen annual double-digit growth rates. Mr. Akin is a significant investor and active strategist for Immune Therapeutics. As an early investor, he was instrumental in the strategic planning and coordination of market penetration, expansion and capitalization.\n\nOutside of the day-to-day operations of Collier, Mr. Akin is an active investor in a variety of emerging growth companies, having served in a number of business roles including Executive Chairman, Independent Board Director, Strategic Advisor, Venture Capital Limited Partner, market pundit, guest speaker/moderator, private investor and trustee. \n\nDr. Selsky has been a p...